<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03130699</url>
  </required_header>
  <id_info>
    <org_study_id>R01DK112322-01A1</org_study_id>
    <nct_id>NCT03130699</nct_id>
  </id_info>
  <brief_title>Dulce Digital-Me: An Adaptive mHealth Intervention for Underserved Hispanics With Diabetes</brief_title>
  <acronym>DD-Me</acronym>
  <official_title>Dulce Digital-Me: An Adaptive mHealth Intervention for Underserved Hispanics With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Whittier Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>San Diego State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Scripps Whittier Diabetes Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare Dulce Digital (i.e., the investigators' proven-effective combination&#xD;
      of &quot;one-size-fits-all&quot; educational text messages and nurse monitoring of patient-transmitted&#xD;
      blood glucose values) and Dulce Digital-Me (DD-Me), an adaptive/dynamic mHealth (mobile&#xD;
      health) intervention that is tailored to individuals' needs and behavioral progress, in&#xD;
      improving diabetes clinical control, adherence, and patient-provider communication in&#xD;
      Hispanics - an at-risk, understudied population that experiences disparities in diabetes&#xD;
      prevalence and outcomes. These striking disparities in the growing and aging US Hispanic&#xD;
      population have taxed the US healthcare system, while significantly reducing quantity and&#xD;
      quality of life for millions of individuals. By offering an innovative, scalable, and&#xD;
      sustainable approach that seamlessly integrates several mHealth technologies into existing&#xD;
      primary care team processes to improve the health of Hispanics (and eventually, other&#xD;
      at-risk, underserved groups), DD-Me has strong potential to significantly impact public&#xD;
      health.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals of low socioeconomic (SES) and ethnic minority status, including Hispanics, the&#xD;
      largest U.S. ethnic minority group, are disproportionately affected by diabetes. Poor&#xD;
      healthcare access and cultural barriers prevent optimal care, adherence, and clinical&#xD;
      benefit, thus placing Hispanics at high risk for costly diabetes complications. The&#xD;
      investigators' established academic-healthcare-community partnership has unique experience in&#xD;
      developing and testing innovative, cost-effective, and sustainable chronic care interventions&#xD;
      to reduce disparities and improve health in underserved communities. The investigators&#xD;
      recently developed Dulce Digital (i.e., &quot;one-size-fits-all&quot; educational text messages, with&#xD;
      nurse monitoring of patient-transmitted blood glucose values), which improved glycemic&#xD;
      control across 6 months, relative to usual care in a recent randomized controlled trial (RCT)&#xD;
      of N=126 Hispanic patients with poorly controlled type 2 diabetes (T2DM). The process&#xD;
      evaluation for this trial indicated that Dulce Digital was both feasible and acceptable from&#xD;
      patient and provider perspectives; however, patients expressed a preference for a more&#xD;
      individualized intervention, and providers requested an even greater focus on health behavior&#xD;
      change. Thus, the proposed RCT will examine the comparative effectiveness of Dulce Digital&#xD;
      versus &quot;Dulce Digital-Me&quot; (DD-Me) in N=414 Hispanic adults of low SES with poorly controlled&#xD;
      T2DM from Neighborhood Healthcare, a San Diego Federally-Qualified Health Center. Guided by&#xD;
      patient and provider feedback, DD-Me includes Dulce Digital components plus personalized&#xD;
      goal-setting and feedback that is responsive to the individual's needs and preferences. The&#xD;
      DD-Me adaptive feedback component will be informed by the Resources and Support for&#xD;
      Self-Management Model and Operant Conditioning Theory, and based on the individual's progress&#xD;
      on intermediate behavioral targets (i.e., medication adherence assessed by wireless sensor;&#xD;
      brief mobile phone-based assessments of diet, physical activity, stress). Feedback will be&#xD;
      delivered via algorithm-driven automated messaging in 50% of DD-Me participants and by the&#xD;
      care team medical assistant in the remaining half to determine the feasibility and&#xD;
      acceptability (given the purported cultural relevance of interpersonal relationships in the&#xD;
      Hispanic culture), and the comparative effectiveness and cost of each delivery method.&#xD;
      Changes in indicators of diabetes clinical control [i.e., glycosylated hemoglobin (HbA1c) low&#xD;
      density lipoprotein cholesterol (LDL-C), systolic blood pressure (SBP)], patient-provider&#xD;
      communication, and patient adherence (i.e., to medication and other diabetes self-management&#xD;
      behaviors) will be evaluated across twelve months. Thorough process and cost-effectiveness&#xD;
      analyses will evaluate the scalability and sustainability potential of DD-Me. This&#xD;
      comparative evaluation of two mHealth approaches will elucidate how technology can be&#xD;
      integrated most effectively and efficiently within existing nurse-led chronic care approaches&#xD;
      to meet the complex needs of underserved individuals with poorly controlled T2DM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 22, 2017</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycosylated Hemoglobin (HbA1c); % units</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Low-density lipoprotein-cholesterol (LDL-C); mg/dL units</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic blood pressure (SBP); mmHg units</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Chronic Illness Care (PACIC) - patient-reported outcome</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Illness Resources Survey (CIRS) - patient-reported outcome</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Diabetes Self-Care Activities (SDSCA) - patient-reported outcome</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Activation Measure (PAM) - patient-reported outcome</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Refills and Medications Scale (ARMS) - patient-reported outcome</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Cost Effectiveness using the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pay for Performance (P4P) Clinical Metrics</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">310</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Dulce Digital</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives one-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dulce Digital-Me (Automated Delivery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The second of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dulce Digital-Me (Medical Assistant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The third of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dulce Digital</intervention_name>
    <description>One-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.</description>
    <arm_group_label>Dulce Digital</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dulce Digital-Me (Automated Delivery)</intervention_name>
    <description>Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.</description>
    <arm_group_label>Dulce Digital-Me (Automated Delivery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dulce Digital-Me (Medical Assistant)</intervention_name>
    <description>Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.</description>
    <arm_group_label>Dulce Digital-Me (Medical Assistant)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Self-identified Hispanic/Latino&#xD;
&#xD;
          2. 18 years or older&#xD;
&#xD;
          3. Registered patient of a Neighborhood Healthcare Clinic&#xD;
&#xD;
          4. Diagnosed with T2DM (Type 2 Diabetes Mellitus)&#xD;
&#xD;
          5. HbA1c ≥ 8.0% and/or SBP ≥ 160 mmHg, and/or LDL-C ≥ 100 mg/dL in the last 30 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe illness precluding regular clinic visits&#xD;
&#xD;
          2. Pregnant or lactating&#xD;
&#xD;
          3. Type 1 or gestational diabetes&#xD;
&#xD;
          4. Lack of minimal literacy&#xD;
&#xD;
          5. Plans to relocate&#xD;
&#xD;
          6. Severe auditory or visual problems&#xD;
&#xD;
          7. Primary language other than Spanish or English&#xD;
&#xD;
          8. Unwilling to carry a mobile phone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athena Philis-Tsimikas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Whittier Diabetes Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda Gallo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Diego State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Mercy Chula Vista</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Whittier Diabetes Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Scripps Whittier Diabetes Institute</investigator_affiliation>
    <investigator_full_name>Athena Philis-Tsimikas</investigator_full_name>
    <investigator_title>Corporate Vice President</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>mHealth</keyword>
  <keyword>Medical Assistant</keyword>
  <keyword>Automated</keyword>
  <keyword>Adaptive Feedback</keyword>
  <keyword>Self-Management Support</keyword>
  <keyword>Hispanics</keyword>
  <keyword>HbA1c</keyword>
  <keyword>Cyberinfrastructure</keyword>
  <keyword>Federally-Qualified Health Centers</keyword>
  <keyword>Cost-Effectiveness</keyword>
  <keyword>T2DM</keyword>
  <keyword>Pay-for-Performance</keyword>
  <keyword>Medication Adherence</keyword>
  <keyword>LDL-C</keyword>
  <keyword>Systolic Blood Pressure</keyword>
  <keyword>Text Messaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

